Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study – SOFIA

Breast care

Gunter von Minckwitz¹  Uwe Fuhr¹  Sibylle Loibl¹  Kathrin Schwedler¹  Keyur Mehta¹  Bettina Conrad¹  Michaela Wüllner¹  Holger Eidtmann¹  Dennis Rokitta¹  Nadia Harbeck¹  Iris Schrader¹  Bernd Gerber¹  Mathias Warm¹ 

[1] aGerman Breast Group, Neu-Isenburg, Germany

关键词: Breast cancer;    Sorafenib;    Pharmacokinetics;    Anthracycline;    Taxane;   

DOI  :  10.1159/000363430

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, ‘SOFIA’.

【 授权许可】

Unknown